Nothing Special   »   [go: up one dir, main page]

CA2439269C - Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds - Google Patents

Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds Download PDF

Info

Publication number
CA2439269C
CA2439269C CA2439269A CA2439269A CA2439269C CA 2439269 C CA2439269 C CA 2439269C CA 2439269 A CA2439269 A CA 2439269A CA 2439269 A CA2439269 A CA 2439269A CA 2439269 C CA2439269 C CA 2439269C
Authority
CA
Canada
Prior art keywords
salt
medicament
alkyl
meta
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2439269A
Other languages
French (fr)
Other versions
CA2439269A1 (en
Inventor
Johannes Bartholomaeus
Heinrich Kugelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to CA2725635A priority Critical patent/CA2725635A1/en
Publication of CA2439269A1 publication Critical patent/CA2439269A1/en
Application granted granted Critical
Publication of CA2439269C publication Critical patent/CA2439269C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/62—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/68—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain with singly-bound oxygen atoms, six-membered aromatic rings and amino groups bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments.

Description

COMPOUNDS
The present invention relates to pharmaceutical salts of an active compound and at least one sugar substitute, medicaments comprising these salts, and the use of these salts for the production of medicaments.
On oral administration, a large number of pharmaceutical active compounds having excellent activity lead to a strongly bitter, often nauseating taste sensation in the patient. In some patients, lack of adherence to the dosage instructions and a lack of acceptance of the corresponding medicaments which release such an active compound as early as during taking result from this negative taste experience.

The formulation of pharmaceutical active compounds having very good water solubility to give medicaments frequently causes problems in pharmaceutical practice.
Thus the---_preparation of pfiarmaceu~ical forms having controlled release is often made difficult on account of the very good water solubility of active compound salts. A delaying of the release of these active compounds can in fact be achieved, for example, by coating the pharmaceutical forms with release-delaying film coatings. This manner of delaying the release, however, is associated with a relatively high outlay, since release-delaying film coatings from aqueous coating systems are frequently only an inadequate diffusion barrier for active compounds having very good water solubility. The preparation of these delayed-release active compound preparations therefore requires relatively complicated coating processes with multilayer films. If such release-delaying coatings are applied from organic solvents, the environmental and solvent residue problems associated therewith additionally make the preparation of appropriate preparations more expensive.
It was therefore the object of the present invention to make available pharmaceutical combinations of active compounds which have no bitter taste. Preferably, the corresponding active compounds should be simpler to formulate and their release should be more effectively delayed.

According to the invention, this object is achieved by the provision of pharmaceutical salts, i . e . physiologically tolerable salts, from a pharmaceutical active compound and at least one sugar substitute.

The present invention therefore relates to pharmaceutical salts of a pharmaceutical active compound and at least one sugar substitute, the respective pharmaceutical salts of a sugar substitute and tramadol, (+)-tramadol, (-)-tramadol, (+)-demethyltramadol and (-)-demethyltramadol being excepted.

In accordance with an aspect of the present invention, there is provided a pharmaceutical salt of a pharmaceutical active compound and at least one sugar substitute, wherein the salt-forming active compound is a salt-forming 1-phenyl-3-dimethylaminopropane compound of the general formula I
~\ CH3 I

in which -2a-X is OH, F, Cl, H or an OCOR6 group, R1 is a C1-4-alkyl group, R2 is H or a C1_4-alkyl group and R3 is H or a straight-chain C1_4-alkyl group or the radicals R2 and R3 together form a C4-7-cycloalkyl radical, and if R5 is H, R4 is meta-O-Z where Z is H, C1_3-alkyl, PO (0-C1-4-alkyl) 2, CO (OC1_5-alkyl) , CONH-C6H4- (C1_3-alkyl) , CO-C6H4-R7, where R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N (R8) 2 where R8 is C1_4-alkyl or 4-morpholino, or R4 is meta-S-C1-3-alkyl, meta-C1, meta-F, meta-CR9R10R" where R9, Rio, R" are H or F, ortho-OH, ortho-O-C2_3-alkyl, para-F or para-CR9R1 R11 where R9, Rio, R'1 are H or F, or if R5 is para-Cl, -F, -OH or -0-C1_3-alkyl, R4 is meta-C1, -F, -OH or -O-C1_ 3-alkyl, or R4 and R5 together are 3,4-OCH=CH- or 3,4-OCH=CHO-, R6 is C1-3-alkyl, in the form of their possible stereoisomers as racemates or diastereomerically pure enantiomers or in the form of mixtures of enantiomers, in which the respective enantiomers are present in nonequimolar amounts.

In a preferred embodiment of the present invention, the solubility of the pharmaceutical salts according to the invention in water is S 250 mg/ml of water, preferably < 200 mg/ml, particularly preferably -<
150 mg/ml, very particularly preferably - 100 mg/ml. This can also be seen in particular in the fact that the water solubility of the pharmaceutical salts according to the invention -2b-compared with the water solubility of the best water-soluble salt of the corresponding active compound according to Pharmazeutische Stoffliste [Pharmaceutical Substance List], 12th edition ABDATA
Pharma-Daten-Service, 65735 Eschborn/Taunus, is preferably lowered by at least 50%, preferably by at least 65%, particularly preferably by at least 75%, very particularly preferably by at least 85%, compared with the corresponding hydrochloride.

According to the invention, suitable sugar substitutes are all sugar substitutes which can form a salt with the respective pharmaceutical active compound with formation of an at least singly negatively charged form. According to the invention, pharmaceutical salts are also included in which the pharmaceutical active compound has two or more different sugar substitutes as salt components. Preferably, the pharmaceutical salts according to the invention contain saccharin, cyclamate or acesulfam, particularly preferably saccharin, as salt-forming sugar substitutes.

According to the invention, suitable active compounds are all pharmaceutical active compounds which can form a salt in anionic form with the respective sugar substitute(s) with formation of an at least singly positively charged form.

In a further preferred embodiment of the present invention, the salt-forming active compound in the pharmaceutical salt according to the invention is selected from the group consisting of the salt-forming analgesics, antiobesity agents, analeptics, anti-hypoxemics, antirheumatics, opioid antagonists, anthelmintics, antiallergics, antiarrhythmics, anti-biotics, antidementives (nootropics), antidiabetics, antiemetics, antivertiginous agents, antiepileptics, antihypertensives, antihypotensives, antimycotics, antiinflammatories, antitussives, expectorants, arteriosclerosis agents, R-receptor blockers, calcium channel blockers, broncholytics, antiasthmatics, cholinergics, diuretics, circulation-promoting agents, weaning agents, geriatrics, hypnotics, sedatives, immunomodulators, oral therapeutics, pharyngeal therapeutics, coronary agents, hypolipidemics, local anesthetics, neural therapeutics, gastric agents, intestinal agents, migraine agents, muscle relaxants, anesthetics, neuropathy preparations, ophthalmo-logicals, otologicals, Parkinson agents, psycho-pharmaceuticals, rhinologicals, sinusitis agents, spasmolytics, platelet aggregation inhibitors, tuberculosis agents, urologicals and cytostatics.
Particularly preferably, the salt-forming active compound is selected from the group consisting of the salt-forming analgesics, analeptics, antihypoxemics, antiallergics, antiarrhythmics, antiemetics, anti-vertiginous agents, antihypertensives, anti-hypotensives, antitussives, expectorants, R-receptor blockers, calcium channel blockers, ophthalmological s, otologicals, spasmolytics and urologicals. Very particularly preferably, the salt-forming active compound is selected from the group consisting of the salt-forming analgesics, tramadol, (+)-tramadol, (-)-tramadol, (+)-demethyltramadol and (-)-demethyltramadol being excepted.

If the pharmaceutical active compound is a salt-forming analgesic, it is preferably a salt-forming opioid or a salt-forming opioid analog, such as disclosed in E. Friderichs, T. Christoph, H. Buschmann, "Analgesics and Antipyretics"; Ullmann's Encyclopedia of Industrial Chemistry, Sixth Edition on CD-ROM, Wiley-VCH, Weinheim, 2000 or in Pharmaceuticals, J.L. McGuire (Editor), Analgesics and Antipyretics, Volume 2, pages 341-434, Wiley-VCH, Weinheim or ephedrine, chloroquine, lidocaine, ethaverine, preglumetacin or triflu-promazine.
Particularly preferably, the salt-forming analgesic is selected from the group consisting of morphine, codeine, ethylmorphine, diacetylmorphine, dihydrocodeine, etorphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone, pethidine, ketobemidone, fentanyl, alfentanil, remifentanil, sufentanil, levomethadone, levomethadyl, dextro-moramide, dextropropoxyphene, diphenoxylate, piri-tramide, tilidine, buprenorphine, butorphanol, dezozine, meptazinol, nalbuphine, nalorphine, pentazo-cine, flupirtin and nefopam or a representative of the group consisting of ephedrine, chloroquine, lidocaine, ethaverine, preglumetacin and triflupromazine. Very particularly preferably, the salt-forming analgesic is a salt-forming opioid or opioid analog selected from the group consisting of morphine, codeine, hydrocodone, hydromorphone, oxycodone, tilidine, fentanyl and buprenorphine.
Likewise preferably, the salt-forming active compound is a salt-forming compound of 1-phenyl-3-dimethylamino-propane compounds of the general formula I

R.

N

I

in which in each case X is OH, F, Cl, H or an OCOR6 group, R1 is a C1_4-alkyl group, R2 is H or a C1-4-alkyl group and R3 is H or a straight-chain C1_4-alkyl group or the radicals R2 and R3 together form a C4_7-cycloalkyl radical, and if R5 is H, R4 is meta-O-Z where Z is H, C1_3-alkyl, PO (O-C1_4-alkyl) 2, CO (OC1-5-alkyl) , CONH-C6H4- (C1_3-alkyl) , CO-C6H4-R7, where R7 is ortho-OCOC1_3-alkyl or meta- or para-CH2N (R8) 2 where R8 is C1_4-alkyl or 4-morpholino, or R4 is meta- S-C1-3-alkyl, meta-Cl, meta-F, meta-CR9R1 R11 where R9, R10 and R'1 are H or F, ortho-OH, ortho-O-C2_3-alkyl, para-F or para-CR9R10R11 where R9, R10, R11 are H
or F, or if R5 is para-Cl, -F, -OH or -0-C1_3-alkyl, R4 is meta-Cl, -F, -OH or -O-Cl-3-alkyl, or R4 and R5 together are 3,4-OCH=CH- or 3,4-OCH=CHO-, R6 is C1_3-alkyl, in the form of their possible stereoisomers as racemates or diastereomerically pure enantiomers or in the form of mixtures of enantiomers, in which the respective enantiomers are present in nonequimolar amounts.

Preferred is a salt-forming compound of 1-phenyl-3-dimethylaminopropane compounds of the general formula I
in which X is OH, F, Cl or H, R1 is a C1_4-alkyl group, R2 is H or CH3 and R3 is H or CH3 and if R5 is H, R4 is meta-O-C1-3-alkyl, meta-OH, meta-S-C1_3-alkyl, meta-F, meta-C1, meta-CH3, meta-CF2H, meta-CF3 or para-CF3 or if R5 is a para-C1 or -F, R4 is meta-C1 or -F, or R4 and R5 together are 3,4-OCH=CH-.

Particularly preferred is a salt-forming compound of 1-phenyl-3-dimethylaminopropane compounds of the general formula I in which the radicals R2 and R3 have different meanings and which are present in the form of their diastereomers having the configuration Ia X H

R' H3C . CH3 la Very particularly preferred is a salt-forming compound of 1-phenyl-3-dimethylaminopropane compounds of the general formula I, selected from the group consisting of (1RS,2RS)-3-(3-dimethylamino-l-hydroxy-l,2-dimethyl-propyl)phenol, (-)-(1R,2R)-3-(3-dimethylamino-l-ethyl-2-methylpropyl)-phenol, (+)-(lS,2S)-3-(3-dimethylamino-l-ethyl-2-methylpropyl)-phenol, (2RS,3RS)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol, (-)-(1S,2S)-3-(3-dimethylamino-l-ethyl-l-fluoro-2-methylpropyl) phenol, (+)-(1R,2R)-3-(3-dimethylamino-l-hydroxy-l,2-dimethyl-propyl)phenol, (+)-(2R,3R)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and (-)-(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol.

The preparation of the salt-forming compounds of 1-phenyl-3-dimethylaminopropane compounds of the general formula I and, if appropriate, the separation into the pure optical antipodes can be carried out according to customary methods known to the person skilled in the art. Preferably, the preparation and, if appropriate, the separation is carried out as described in DE-A-4426245 or EP 0 693 475 B1, In a further preferred embodiment of the present invention, the pharmaceutical salt according to the invention contains as a salt-forming active compound a salt-forming compound of 6-dimethylaminomethyl-1-phenylcyclohexane compounds of the general formula II, OR4' R

Rr R3, CH3 II

in which in each case R" is H, OH, Cl or F, preferably H, OH or F, R2' and R3' are identical or different and are H, C1_4-alkyl, benzyl, CF3, OH, OCH2-C6H5, O-C1_4-alkyl, C1 or F
with the proviso that at least one of the radicals R2.
or R31 is H, R4' is H, CH3, PO (O-C1_4-alkyl) 2, CO (OC1_5-alkyl) , CO-NH-C6H4-C1_3-alkyl, CO-C6H4-R5" CO-C1-5-alkyl, CO-CHR6'-NHR7' or an unsubstituted or substituted pyridyl, thienyl, thiazoyl [sic] or phenyl group, R5' is OC (0) C1_3-alkyl in the ortho-position or CH2-N (R8') 2 in the meta- or para-position, where R8' is C1-4-alkyl or both radicals R8' together with N are the 4-morpholino radical, and R6` and R7' are identical or different and are H or C1-6-alkyl, with the proviso that if both radicals R2' and R3 ' are H, R4' is not CH3 if R" is H, OH or Cl or R4' is not H if R11 is OH, in the form of their possible stereoisomers as racemates or diastereomerically pure enantiomers or in the form of mixtures of enantiomers, in which the respective enantiomers are present in nonequimolar amounts.
Preferred are salt-forming compounds of 6-dimethylaminomethyl-1-phenylcyclohexane compounds of the general formula II, which are present in the configuration as in the general formula IIa, Rr W, C

IIa in which the phenyl ring and the dimethylaminomethyl group are in each case arranged in an equatorial position to one another.

Particularly preferred is a salt-forming compound of 6-dimethylaminomethyl-l-phenylcyclohexane compounds of the general formula II selected from the group consisting of (-)-(1R,2R)-3-(2-dimethylaminomethylcyclohexyl)phenol, (1RS,3RS,6RS)-6-(dimethylaminomethyl)-1-(3-methoxy-phenyl)cyclohexane-1,3-diol and (1RS,3RS,6RS)-6-(dimethylaminomethyl)-l-(3-hydroxy-phenyl)cyclohexane-1,3-diol.
The preparation of the salt-forming compounds of 6-dimethylaminomethyl-l-phenylcyclohexane compounds of the general formula II and, if appropriate, the separation into the optically pure antipodes can be carried out according to customary methods known to the person skilled in the art. Preferably, the preparation and, if appropriate, the separation are carried out as described in DE-A-19525137.

In a further preferred embodiment of the present invention, the pharmaceutical salt according to the invention contains as a salt-forming active compound a salt-forming compound of 1-phenyl-2-dimethylamino-methylcyclohexan-1-ol compounds of the general formula III, 1' /R
A
Rr/Y------Z

OH

Ill in which in each case A is 0 or S, R"' is H, C1_6-alkyl, C2_6-alkenyl, C5-7-cycloalkyl or halogenated C1_6-alkyl, the group -Y=Z\
is the group / /
CFi~--C; I ---CH-< or -~-O--C~

R2 is C1_6-alkyl, C2-6-alkenyl, C5-7-cycloalkylmethyl, substituted or unsubstituted phenyl or substituted or unsubstituted benzyl, in the form of their possible stereoisomers as racemates or diastereomerically pure enantiomers or in the form of mixtures of enantiomers, in which the respective enantiomers are present in nonequimolar amounts.

Preferred are salt-forming compounds of 1-phenyl-2-di-methylaminomethylcyclohexan-l-ol compounds of the general formula III, in which R" is H, C1_4-alkyl, 2' -methyl-2'-propenyl, cyclopentyl or fluoroethyl, with the proviso that R"' is C1-4-alkyl if A is S, R2. f is C1_4-alkyl, C2_4-alkenyl, cyclopentylmethyl, phenyl, C1_4-alkoxyphenyl, benzyl, C1_4-alkylbenzyl, mono- or dihalogenated phenyl or mono- or dihalogenated benzyl.

Particularly preferred are salt-forming compounds of 1-phenyl-2-dimethylaminomethylcyclohexan-l-ol compounds of the general formula III, in which R"' is H, methyl, ethyl, isopropyl, 2'-methyl-2'-propenyl, cyclopentyl or fluoroethyl, with the proviso that R11' is methyl if A
is S, R2" is methyl, propyl, 2'-methylpropyl, allyl, 2'-methyl-2'-propenyl, cyclopentylmethyl, phenyl, 3-methoxyphenyl, benzyl, 4-tert-butylbenzyl, 4-chloro-benzyl, 4-fluorobenzyl or 3,4-dichlorobenzyl.

Very particularly preferred are salt-forming compounds of 1-phenyl-2-dimethylaminomethylcyclohexan-l-o1 compounds of the general formula III which are present in the configuration of the formula IIIa, A' OH
Rte/
N
"-CH3 , Ilia in which the phenyl ring and the dimethylaminomethyl group are in each case arranged in an equatorial position to one another.

Most preferred is the salt-forming compound of 1-phenyl-2-dimethylaminomethylcyclohexan-l-ol compounds of the general formula III selected from the group consisting of (+)-(1R,2R,4S)-2-(dimethylaminomethyl)-4-(4-fluoro-benzyloxy)-1-(3-methoxyphenyl)cyclohexanol, (+)-(1R,2R,4S)-2-dimethylaminomethyl-4-(4-chloro-benzyloxy)-1-(3-methoxyphenyl)cyclohexanol and (+)-(1R,2R,4S)-3-[2-dimethylaminomethyl-4-(4-fluoro-benzyloxy)-l-hydroxycyclohexyl]phenol.
The preparation of the salt-forming compounds of 1-phenyl-2-dimethylaminomethylcyclohexan-l-ol compounds of the general formula III and, if appropriate, the separation into the optically pure antipodes can be carried out according to customary methods known to the person skilled in the art. Preferably, the preparation and, if appropriate, the separation are carried out as described in DE-A-19547766.
In a further preferred embodiment of the present invention, the pharmaceutical salt contains as a salt-forming active compound a salt-forming compound of dimethyl-(3-arylbut-3-enyl)amine compounds of the general formula IV, in which [sic]

Rs~

R
H
Rr, CH3 Rr R''" CH3 IV

the radical R1, . . is C1_5-alkyl and R2. . . is H or C1_5-alkyl or R1... and R2... together are - (CH2) 2-4-, - (CH2) 2-CHR7"' or -CH2-CHR71 " -CH2-, R 3" is H or C1_5-alkyl, pd" is H, OH, C1_4-alkyl, O-C1_4-alkyl, O-benzyl, CF3r 0-CF3r Cl, F or ORB", R5,,, is H, OH, C1_4-alkyl, O-C1-4-alkyl, O-benzyl, CHF2, CF3, O-CF3, Cl, F or OR8and R6" is H, OH, C1_4-alkyl, O-C1_4-alkyl, O-benzyl, CF3r 0-CF3, Cl, F or OR8t , with the proviso that two of the radicals R4111 , R511' or R6are H, or R4 '. , and R5... together are -CH=C (R9...) -0- or -CH=C (R9. . .) -S-, with the proviso that R6. . . is H, or R5 . . . and R6 ' . , together are -CH=CH-C (OR10 ') =CH- , with the proviso that R4. . . is H, R7... is C1_8-alkyl, C3_8-cycloalkyl, O-C1-4-alkyl, 0-benzyl, CF3, Cl or F, R8... is CO-C1-5-alkyl, PO (O-C1_4-alkyl) 2, CO-C6H4-R11 , CO (O-C1-5-alkyl) , CO-CHR12 ' -NHR13' ' ' , CO-NH-C6H3- (R14...) 2 or an unsubstituted or substituted pyridyl, thienyl, thiazoyl [sic] or phenyl group, R9. . . is H or Cl_4-alkyl, R10.. . is H or C1-3-alkyl, R11. . . is OC (O) -C1-3-alkyl in the ortho-position or CH2-N-(R15" ) 2 in the meta- or para-position, where R15... is C1-4-alkyl or both radicals R151 ' together with N form the 4-morpholino radical, R12' II and R13. . . are identical or different and are H, C1-6-alkyl or C3-8-cycloalkyl or R12" , and R13together are - (CH2) 3-8-, R14. . . is H, OH, C1-7-alkyl, O-C1_7-alkyl, phenyl, 0-aryl, CF3, Cl or F, with the proviso that the two radicals R14... are identical or different, in the form of their possible stereoisomers as racemates or diastereomerically pure enantiomers or in the form of mixtures of enantiomers, in which the respective enantiomers are present in nonequimolar amounts.
Preferred are salt-forming compounds of dimethyl-(3-arylbut-3-enyl)amine compounds of the general formula IV, in which R1"' is C1_3-alkyl and R2"' is H or C1-3-alkyl, or R1"' and R2"' together are - (CH2) 2_4- or - (CH2) 2-CHR7"', R3' " is H or C1_3-alkyl, R4''' is H, OH, CF3, Cl, F or OR8"', R5"' is H, OH, C1_4-alkyl, O-C1-4-alkyl, 0-benzyl, CHF2, CF3, Cl, F or OR8' B", and R6"' is H, OH, O-C1-4-alkyl, 0-benzyl, CF3, Cl, F or OR$

with the proviso that two of the radicals R4"', R5"' or R6''' are H, or R4and R5"' together are -CH=C(R 9... )_O_ or -CH=C(R9"')-S-, with the proviso that R6"' is H, or R5' ' ' and R6' ' ' together are -CH=CH-C (OR10' ' ')=CH-, with the proviso that R4'" is H, and R7"' is C1_4-alkyl, CF3, Cl or F.

Particularly preferred are salt-forming compounds of dimethyl-(3-arylbut-3-enyl)amine compounds of the general formula IV, in which R1"' is CH3 or C3H7 and R2"' is H, CH3 or CH2CH3, or Rl"' and R2"' together are - (CH2) 2-3- or - (CH2) 2-CHR7"' , R3"' is H, CH3 or CH2CH3, R4"' is H or OH, R5"' is H, OH, OCH3, CHF2 or OR 8... and R6" . is H, OH or CF3, with the proviso that two of the radicals R4"' , R5"' or R6"' are H, or R4. . . and R5... together are -CH=C (CH3) -S-, with the proviso that R6111 is H, or R51,, and R61 together are -CH=CH-C (OH) =CH-, with the proviso that R4. . . is H, and R" is CO-C6H4-Rl" where R11... is OC (O) -C1_3-alkyl in the ortho-position.

Very particularly preferred are salt-forming compounds of dimethyl-(3-arylbut-3-enyl)amine compounds of the general formula IV, in which R1... is CH3 and R2. ' is H or CH3 or R1... and R2.. . together are - (CH2) 2_3- or - (CH2) 2-CH (CH3) -, R3... is H or CH3, 4õ
Ris H, R-"" is OH or ORB"', R6õ . is H, and R"õ is CO-C6H4-R1110' where R11... is OC (O) -CH3 in the ortho-position.
Most preferred is the salt-forming compound of dimethyl-(3-arylbut-3-enyl)amine compounds of the general formula IV trans-(-)-(1R)-3-[1-(2-dimethylamino-l-methylethyl)propenyl]phenol.

The preparation of the salt-forming compounds of dimethyl-(3-arylbut-3-enyl)amine compounds of the general formula IV and, if appropriate, the separation into the optically pure antipodes can be carried out according to customary methods known to the person skilled in the art. Preferably, the preparation and, if appropriate, the separation of these compounds are carried out as described in EP 0 799 819 Al.
As salt-forming antiobesity agents, the pharmaceutical salt according to the invention can preferably contain D-norpseudoephedrine, phenylpropanolamine, amfepramone, mefenorex or ephedrine.
As salt-forming analeptics and/or antihypoxemics, the pharmaceutical salt according to the invention can preferably contain norfenefrine, heptaminol or amezinium, particularly preferably amezinium.
As salt-forming opioid antagonists, the pharmaceutical salt according to the invention can preferably contain levallorphan, naloxone or naltrexone.

As a salt-forming anthelmintic, the pharmaceutical salt according to the invention can preferably contain pyrvinium.

As salt-forming antiallergics, the pharmaceutical salt according to the invention can preferably contain reproterol, triprolidine, hydroxyzine, azelastine, diphenhydramine, promethazine, pheniramine, dexchlor-pheniramine, clemastine, tramazoline, brompheniramine, dimetindene, levocabastine, doxylamine, cyproheptadine, carbinoxamine, meclozine, bamipine, chlorphenoxamine, ketotifen or cetirizine, particularly preferably diphenhydramine.

As salt-forming antiarrhythmics, the pharmaceutical salt according to the invention can preferably contain orciprenaline, aprindine, verapamil, metoprolol, quinidine, amiodarone, sotalol, propafenone, diltiazem, disopyramide, propranolol, ipatropium [sic], mexiletine, prajmaline, procainamide, gallopamil, propafenone, detajmium, flecainide, oxprenolol or tocainide, particularly preferably verapamil or diltiazem.
As salt-forming antibiotics, the pharmaceutical salt according to the invention can preferably contain vancomycin, tetracycline, clindamycin, minocycline, lincomycin, bacampicillin, amicacin, chlortetracycline, neomycin, tobramycin, netilmicin, quinine, chloroquine, ciprofloxacin, clindamycin, colistine, erythromycin, gentamicin, tobramycin [sic], cefetametpivotil, amantadine, halofantrine, saquinavir, mefloquine, framycetin, cefepime, bromhexine, cefpodoximeproxetil, oxytetracycline, proguanil, pefloxacine, polymyxin B, hydroxychioroquine, spectinomycin, sultamicillin, valaciclovir or grepafloxacin.

As salt-forming antidementive (nootropics), the pharmaceutical salt according to the invention can preferably contain butalamine, memantine, pyritinol, donepezil, moxaverine, meclofenoxate, dihydroergotoxin, viquidil, naftidrofuryl, dihydroergocornine, dihydroergocristine, benzyclan, procaine, deamol, diisopropylamine or 3-pyridylmethanol.

As a salt-forming antidiabetic, the pharmaceutical salt according to the invention can preferably contain metformin.
As salt-forming antiemetics and/or antivertiginous agents, the pharmaceutical salt according to the invention can preferably contain betahistidine, dolasetrone, meclozine, hydroxycine, diphenhydramine, pyridoxine, granisetrone, triflupromazine, triethyl-perazine, betahistine, alizapride or odansetrone, particularly preferably diphenhydramine.

As a salt-forming antiepileptic, the pharmaceutical salt according to the invention can preferably contain tiagabine.

As salt-forming antihypertensives, the pharmaceutical salt according to the invention can preferably contain dihydralazine, prazosine, amiloride, bunazosine, nicardipine, alprenolol, candesartancilexetil, metoprolol, verapamil, propranolol, penbutolol, doxazosine, clonidine, benazepril, phenoxybenzamine, diltiazem, diisopropylamine, urapide, carteolol, guanethidine, guanfacine, terazosine, oxprenolol, cicletanine, betaxolol, nebivolol, acebutolol, enalapril or indoramine, particularly preferably verapamil or diltiazem.
As salt-forming antihypotensives, the pharmaceutical salt according to the invention can preferably contain etilefrine, pholedrine, norfenefrine, cafedrine, theodrenaline, oxilofrine, dobutamine, dopamine, phenylephrine, midodrine, heptaminol, oxedrine tartrate, pholedrine or gepefrine, particularly preferably phenylephrine.

As salt-forming antimycotics, the pharmaceutical salt according to the invention can preferably contain benzalkonium, econazole, miconazole, methyl-rosanilinium, terbinafine, amorolfine, fenticonazole, dequalinium, oxyconazole, croconazole, isoconazole or sertaconazole.
As a salt-forming antiinflammatory, the pharmaceutical salt according to the invention can preferably contain orphenadrine.

As salt-forming antitussives and/or expectorants, the pharmaceutical salt according to the invention can preferably contain ambroxole, doxycycline, bromhexine, dextromethorphan, diphenhydramine, terbutaline, chlorphenamine, eprazinone, ephedrine, chlorbutinol, pentoxyverine, pipazetate or benproperine, particularly preferably diphenhydramine.
As a salt-forming antisclerosis agent, the pharmaceutical salt according to the invention can preferably contain butalamine.

As (3-receptor blockers and/or calcium channel blockers, the pharmaceutical salt according to the invention can preferably contain acebutolol, nicardipine, alprenolol, metoprolol, verapamil, enalapril, bupranolol, penbutolol, propranolol, bisoprolol, esmolol, celiprolol, benazepril, diltiazem, mepindolol, sotalol, carteolol, gallopamil or oxprenolol, particularly preferably verapamil or diltiazem.

As salt-forming broncholytics and/or antiasthmatics, the pharmaceutical salt according to the invention can preferably contain ketotifen, reproterol, orciprenaline, salbutamol, terbutaline, ephedrine, tulobuterol, ipatropium [sic], fenoterol, terbutaline [sic], formoterol, salbutamol [sic], oxytropium or pirbuterol.

As salt-forming cholinergics, the pharmaceutical salt according to the invention can preferably contain pyridostigmine, betanechol or neostigmine..
As salt-forming diuretics, the pharmaceutical salt according to the invention can preferably contain amiloride or oxprenolol.

As salt-forming, circulation-promoting agents, the pharmaceutical salt according to the invention can preferably contain butalamine, naftidrofuryl, buflomedil, moxaverine, bencyclan or meclofenoxate.

As a salt-forming weaning agent, the pharmaceutical salt according to the invention can preferably contain naltrexone, methadone, buprenorphine.
As salt-forming geriatrics, the pharmaceutical salt according to the invention can preferably contain procaine or deanolace.

As salt-forming hypnotics and/or sedatives, the pharmaceutical salt according to the invention can preferably contain promethazine, zolpidem tartrate, midazolam, melperone or flurazepam.

As a salt-forming immunomodulator, the pharmaceutical salt according to the invention can preferably contain levamisole.

As salt-forming oral and/or pharyngeal therapeutics, the pharmaceutical salt according to the invention can preferably contain chlorhexidine or cetylpyridinium.

As a salt-forming coronary agent, the pharmaceutical salt according to the invention can preferably contain oxyfedrine.

As a salt-forming hypolipidemic, the pharmaceutical salt according to the invention can preferably contain colestipol.
As salt-forming local anesthetics and/or neural therapeutics, the pharmaceutical salt according to the invention can preferably contain bupivacaine, lidocaine, mepivacaine, ropivacaine, procaine, articaine or prilocaine.

As salt-forming gastric and/or intestinal agents, the pharmaceutical salt according to the invention can preferably contain pizotifen, pirenzepine, roxatidine, ranitidine, butinoline, methanthelinium or metoclopramide.

As salt-forming migraine agents, the pharmaceutical salt according to the invention can preferably contain lisuride, methysergide, dihydroergotamine, ergotamine, sumatriptan, rizatriptan or naratriptan.

As salt-forming muscle relaxants, the pharmaceutical salt according to the invention can preferably contain alcuronium, mivacuronium, atracurium, vecurmium, pancurmium, suxamethonium, tolperisone, pridinol, orphenadrine or tizamidine.

As a salt-forming anesthetic, the pharmaceutical salt according to the invention can preferably contain ketamine or midazolam.

As a salt-forming neuropathy preparation, the pharmaceutical salt according to the invention can preferably contain thiamine.

As salt-forming ophthalmologicals and/or otologicals, the pharmaceutical salt according to the invention can preferably contain oxybuprocaine, proxymetacaine, kanamycin, tolazoline, tetryzoline, tramazoline, phenylephrine, xylomethazoli [sic], naphazoline, timolol, metipranolol, betaxolol, befunolol, levobunolol, brimonidine, clonidine, pilocarpine, dipivefrine, aceclidine, apraclonidine, neostigmine, dorzolamide, atropine, scopolamine, cyclopentolate or homatropine, particularly preferably phenylephrine.

As salt-forming Parkinson agents, the pharmaceutical salt according to the invention can preferably contain amantadine, biperidene, selegiline, bromocriptine, trihexyphenidyl, metrixene, benzaseride, lisuride, benzatropine, ropinirol, pergolide, bupidine, procyclidine, pramipexol, bomapine or tiapride.
As salt-forming psychopharmaceutical agents, the pharmaceutical salt according to the invention can preferably contain tranylcypromine, amitriptyline, doxepine, maprotiline, clomipramine, opipramol, imipramine, trimipramine, lofepramine, desipramine, dibenzepine, nortriptyline, mianserine, citalopram, fluvoxamine, fluoxetil, trazodone, paroxetin, nefazodone, sertralin, viloxacin, venlafaxine, promethazine, chlorprothixene, zuclopenthixol, pipamperone, fluphenazine, flupentixol, melperone, prothipendyl, thioridazine, levomepromazine, quetiapine, triflupromazine, perazine, fenetylline, methylphenidate, hydroxycine, buspirone, deanolace or memantine.

As salt-forming rhinologicals/sinusitis agents, the pharmaceutical salt according to the invention can preferably contain diphenylpyraline, xylometazoline, oxymetazoline, tramazoline, indanazoline, naphazoline or tetryzoline.

As salt-forming spasmolytics, the pharmaceutical salt according to the invention can preferably contain atropine, phenamazide, butylscopolaminium, propiverine, mebeverine, pipenzolate, oxybutynine, flavoxate, trospium, denaverine or glycopyrronium.

As salt-forming platelet aggregation inhibitors, the pharmaceutical salt according to the invention can preferably contain tirofiban, ticlopidine or clopidogrel.

As a salt-forming tuberculosis agent, the pharmaceutical salt according to the invention can preferably contain ethambutol.

As salt-forming urologicals, the pharmaceutical salt according to the invention can preferably contain choline, tolterodine, phenoxybenzamine, atropine, propiverine, distigmine, emepronium, tamsulosine, doxazosine, terazosine, alfuzosine, bamethane, yohimbine or sildenafil.
As salt-forming cytostatics, the pharmaceutical salt according to the invention can preferably contain aclarubicin, nimustatin, doxorubicin, bleomycin, vinblastine, vincristine, daunorubicin, decarbazine, vindesine, epirubicin, gemcitabine, procarbazil, mitoxantrone, bedamustine, idarubicin, aclarubicin [sic], irinotecan, topotecan, toremifen or tamoxifen.
The pharmaceutical salts according to the invention can be prepared according to customary methods known to the person skilled in the art. Preferably, for the preparation of the pharmaceutical salts according to the invention, at least one salt of the respective active compound and at least one salt of the respective sugar substitute are in each case dissolved separately from one another in an amount of a solvent or solvent mixture which is as small as possible, optionally with warming.

Both solutions are then combined, optionally mixed and optionally cooled. If the pharmaceutical salt according to the invention of the active compound and the sugar substitute precipitates at least partially from the optionally cooled solution, this is separated off according to customary methods, preferably by suction filtration. The pharmaceutical salt separated off is then purified, if necessary, according to customary methods known to the person skilled in the art, for example by recrystallization, washing or by stirring in a suitable solvent.
If the pharmaceutical salt has still not completely precipitated, the remaining solution is preferably concentrated completely on a rotary evaporator and the pharmaceutical salt according to the invention is extracted from the residue according to customary methods known to the person skilled in the art and purified as described above.
The solvent or solvent mixture suitable in each case for the preparation and the suitable reaction conditions, such as, for example, temperature or reaction time, can be determined by the person skilled in the art with the aid of simple preliminary tests. If both the active compound salt and the salt of the sugar substitute have an adequate solubility in water, the solvent used is preferably water. The salt of the respective active compound employed is preferably its hydrochloride, hydrobromide, phosphate, hydrogen-phosphate, hydrogensulfate, sulfate, nitrate or metilsulfate. The salt of the respective sugar substitute employed is preferably its sodium, potassium, calcium or ammonium salt.
Of course, it is also possible to react the respective active compound per se with [sic] the free acid of a sugar substitute with one another in a suitable reaction medium and to isolate and, if appropriate, to purify the pharmaceutical salt thus obtained according to customary methods known to the person skilled in the art.

A further subject of the present invention are medicaments comprising at least one pharmaceutical salt according to the invention and, if appropriate, physiologically tolerable excipients. The corresponding medicaments can be used for the treatment of the indications known for the respective active compounds.
Preferably, medicaments according to the invention which contain at least one pharmaceutical salt according to the invention of a salt-forming opioid, opioid analog, ephedrine, chloroquine, lidocaine, ethaverine, preglumetacin or triflupromaazine or a salt-forming compound of the general formula I, II, III
or IV indicated above and a sugar substitute are employed for the control of pain. Preferably, the medicaments according to the invention contain the corresponding saccharinates as pharmaceutical salts of these active compounds.

For the treatment of urinary incontinence, medicaments according to the invention are preferably employed which contain at least one pharmaceutical salt of a salt-forming compound of the general formula I, II, III
or IV indicated above, or a compound from the group consisting of oxybutymine, tolterodine, propiverine and trospium and a sugar substitute. Preferably, the medicaments according to the invention contain the corresponding saccharinates as pharmaceutical salts of these active compounds.

The medicaments according to the invention can be present in solid, semisolid or liquid form. Preferably, the medicaments according to the invention are suitable for oral administration.

In a preferred embodiment, the medicament according to the invention is present-, formulated as a gel, chewing gum, juice, spray, tablet, chewable tablet, coated tablet, powder, if appropriate filled into capsules, easily reconstitutable dry preparations, preferably as a gel, as an aqueous or oily juice, as a sublingual spray, tablets or chewable tablets.

Likewise preferably, the medicament according to the invention can also be present formulated in multiparticulate form, preferably in the form of micro-tablets, microcapsules, granules, active compound crystals or pellets, particularly preferably in the form of microtablets, granules or pellets, optionally filled into capsules or compressed to give tablets.
If the medicament according to the invention is present in the form of granules or pellets, these can preferably have a size in the range from 0.1 to 3 mm, particularly preferably in the range from 0.5 to 2 mm.
If the medicament according to the invention is present in the form of microtablets, these can preferably have a diameter in the range from 0.5 to 5 mm, particularly preferably in the range from 1 to 3 mm and very particularly preferably in the range from 1 to 2 mm.

If the medicament according to the invention is present in the form of active compound crystals, micro-particles, micropellets or microcapsules, these can preferably have a diameter in the range from 10 pm to 1 mm, particularly preferably in the range from 15 pm to 0.5 mm and very particularly preferably in the range from 30 pm to 200 pm.
Depending on embodiment, the medicaments according to the invention can moreover contain the customary physiologically tolerable excipients known to the person skilled in the art as further constituents.
If the medicaments according to the invention are present in the form of tablets or microtablets, these can be present as physiologically tolerable excipients, preferably microcrystalline cellulose, cellulose ethers, lactose, starch, starch derivatives, sugar alcohols, calcium hydrogenphosphate and the customary binders, flow regulators, lubricants and/or disintegrants known to the person skilled in the art.

If the medicaments according to the invention are present in the form of gels or chewing gums, these can preferably contain methylparaben, propylparaben, xylitol and/or xanthan gum as physiologically tolerable excipients.
If the medicaments according to the invention are present in the form of pellets, granules or micro-pellets, these can preferably contain microcrystalline cellulose, cellulose ethers, lactose, starch and starch derivatives, sugar alcohols, calcium hydrogenphosphate, fatty alcohols, esters of glycerol or fatty acid esters as physiologically tolerable excipients.

If the medicaments according to the invention are present in the form of microcapsules or microparticles, these can contain, depending on the nature of the process employed for their preparation, the customary physiologically tolerable excipients known to the person skilled in the art.

The medicaments according to the invention can be prepared by customary methods known to the person skilled in the art.
If the medicaments according to the invention are present in the form of tablets, preferably the pharmaceutical salt according to the invention and, if appropriate, the physiologically tolerable excipients are preferably mixed homogeneously with one another, processed to give granules by means of moist, dry or melt granulation and compressed to give tablets or produced by direct tableting of the pharmaceutical salt with further excipients. In addition, the tablets can preferably be produced by compression of optionally coated pellets, active compound crystals, micro-particles or microcapsules.

The medicaments according to the invention in the form of pellets can preferably be produced by mixing the pharmaceutical salt and physiologically tolerable excipients, extrusion and spheronization, by build-up pelletization or by direct pelletization in a high-speed mixer or in the rotor fluidized bed. The pellets are particularly preferably prepared by extrusion of moist masses and subsequent spheronization.
Microcapsules are prepared according to customary microencapsulation processes, such as, for example, by spray drying, spray solidification or coacervation.

The medicaments according to the invention in semisolid form, such as, for example, gels or chewing guns, are preferably suitable for the administration of the pharmaceutical salt according to the invention via the oral mucosa, the medicaments according to the invention in solid or liquid form, such as, for example, oily or aqueous juices, tablets or multiparticulate forms are preferably suitable for the administration of the pharmaceutical salt according to the invention via the gastric tract. If the absorption of active compound from the medicament according to the invention in solid form is only intended via the gastric tract, they must have at least one enteric coating. This enteric coating enables them to pass through the gastric tract undissolved and the pharmaceutical salt is only released in the intestinal tract. Preferably, the enteric coating dissolves at a pH of between 5 and 7.5.
The medicament according to the invention can contain the pharmaceutical salt according to the invention also partially or completely in delayed-release form.

The delaying of the release of active compound is preferably based on the application of a release-delaying coating, on embedding in a release-delaying matrix, binding to an ion-exchange resin or on a combination of these abovementioned release-delaying methods.

Preferably, the release-delaying coating is based on a water-insoluble, optionally modified natural or synthetic polymer or on a natural, semisynthetic or synthetic wax or fat or fatty alcohol or a mixture of at least two of these abovementioned components.
Water-insoluble polymers employed for the preparation of a release-delaying coating are preferably poly-(meth)acrylates, particularly preferably poly (C14) alkyl (meth) acrylates, poly (C1_4) dialkylamino- (C1-4) -alkyl (meth)acrylates and/or their copolymers, very particularly preferably ethyl acrylate/methyl methacrylate copolymers having a molar ratio of the monomers of 2:1, ethyl acrylate/methyl methacrylate/trimethylammonium ethyl methacrylate chloride copolymers having a molar ratio of the monomers of 1:2:0.1, ethyl acrylate/methyl methacrylate/trimethylammonium ethyl methacrylate chloride copolymers having a molar ratio of the monomers of 1:2:0.2 or a mixture of at least two of these abovementioned polymers as a coating material.

These coating materials are obtainable on the market as 30% strength by weight aqueous latex dispersions under the names Eudragit RS30D , Eudragit NE30D and Eudragit RL30D and are preferably also employed as a coating material as such.

Likewise preferably, the water-insoluble polymers employed for the preparation of the release-delaying coating for the medicaments according to the invention can be polyvinyl acetates, optionally in combination with further excipients. These are obtainable on the market as an aqueous dispersion containing 27% by weight of polyvinyl acetate, 2.5% by weight of povidone and 0.3% by weight of sodium lauryl sulphate (Kollicoat SR 30 D ) .

In a further preferred embodiment, the release-delaying coatings of the medicaments according to the invention are based on water-insoluble cellulose derivatives, preferably alkylcelluloses, such as, for example, ethylcellulose, or on cellulose esters, such as, for example, cellulose acetate, as a coating material. The coatings of ethylcellulose or cellulose acetate are preferably applied from aqueous pseudolatex dispersion.
Aqueous ethylcellulose-pseudolatex dispersions are stocked on the market as 30% strength by weight dispersions (Aquacoat ) or as 25% strength by weight dispersions (Surelease ) and as such are preferably also employed as a coating material.

As natural, semisynthetic or synthetic waxes, fats or fatty alcohols, the release-delaying coating in the medicament according to the invention can preferably contain carnauba wax, beeswax, glycerol monostearate, glycerol monobehenate (Compritol AT0888 ), glycerol ditripalmitostearate (Precirol AT05 ), microcrystalline wax, cetyl alcohol, cetylstearyl alcohol, or a mixture of at least two of these components.

If the release-delaying coating is based on a water-insoluble, optionally modified natural and/or synthetic polymer, the coating dispersion or solution can contain, in addition to the corresponding polymer, a customary physiologically tolerable plasticizer known to the person skilled in the art in order to lower the minimum film temperature necessary.

Suitable plasticizers are, for example, lipophilic diesters of an aliphatic or aromatic dicarboxylic acid of C6-C40 and an aliphatic alcohol of C1-C8, such as, for example, dibutyl phthalate, diethyl phthalate, dibutyl sebacate or diethyl sebacate, hydrophilic or lipophilic esters of citric acid, such as, for example, triethyl citrate, tributyl citrate, acetyltributyl citrate or acetyltriethyl citrate, polyalkylene glycols, such as, for example, polyethylene glycols or propylene glycols, esters of glycerol, such as, for example, triacetin, Myvacet (acetylated mono- and diglycerides, C23H4405 to C25H4707) , medium-chain triglycerides (Miglyol ) , oleic acid or mixtures of at least two of the abovementioned plasticizers.
Preferably, aqueous dispersions of Eudragit RS and optionally Eudragit RL contain triethyl citrate as a plasticizer.

Preferably, the release-delaying coating contains the plasticizer(s) in amounts of 5 to 50% by weight, particularly preferably 10 to 40% by weight and very particularly preferably 10 to 30% by weight, based on the amount of the polymer employed.
In individual cases, for example for cellulose acetate, higher amounts of plasticizers, preferably up to 110%
by weight, based on the amount of cellulose acetate, can also be employed.
In addition, the release-delaying coating can contain further customary excipients known to the person skilled in the art, such as, for example, lubricants, preferably talc or glycerol monostearate, color pigments, preferably iron oxides or titanium dioxide, or surfactants, such as,-.for example, Tween 80 .

The release profile of the delayed active compound component can be adjusted by the customary methods known to the person skilled in the art, such as, for example, by the thickness of the coating or by the use of further excipients as constituents of the coating.
Suitable excipients are, for example, hydrophilic or pH-dependent pore-forming agents, such as, for example, sodium carboxymethylcellulose, cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, lactose, polyethylene glycol or mannitol or water-soluble polymers, such as, for example, polyvinylpyrrolidone or water-soluble celluloses, preferably hydroxypropylmethylcellulose or hydroxy-propylcellulose.
The release-delaying coating can also contain insoluble or lipophilic excipients, such as, for example, alkylized silicone, which is stocked on the market, for example, as Aerosil R972 , or magnesium stearate for the further intensification of the delaying.

The respective formulation of the medicament according to the invention can optionally also contain, in addition to the release-delaying coating, at least one further coating. This can be, for example, a coating for improving the taste or an enteric coating.

The enteric coating is preferably based on methacrylic acid/methyl methacrylate copolymers having a molar ratio of the respective monomers of 1:1 (Eudragit L ), methacrylic acid/methyl methacrylate copolymers having a molar ratio of the respective monomers of 1:2 (Eudragit S ), methacrylic acid/ethyl acrylate copolymers having a molar ratio of the respective monomers of 1:1 (Eudragit L30D-55 ), methacrylic acid/methyl acrylate/methyl methacrylate copolymers having a molar ratio of the respective monomers of 7:3:1 (Eudragit FS ), shellac hydroxy-propylmethylcellulose acetate succinate, cellulose acetate phthalate or a mixture of at least two of these abovementioned components, which can optionally also be employed in combination with the abovementioned water-insoluble poly(meth)acrylates, preferably in combination with Eudragit NE30D and/or Eudragit RL
and/or Eudragit RS .

The coatings can be applied by customary processes suitable for the respective coating and known to the person skilled in the art, such as, for example, by spraying on solutions, dispersions or suspensions, by melt processes or by powder application processes. The solutions, dispersions or suspensions can be employed in the form of aqueous and/or organic solutions or dispersions. In this context, aqueous dispersions are preferably employed. Organic solvents which can preferably be used are alcohols, for example ethanol or isopropanol, ketones, such as, for example, acetone, esters, for example ethyl acetate, chlorinated hydrocarbons, such as, for example, dichloromethane, with alcohols or ketones being particularly preferably employed. It is also possible to employ mixtures of at least two of the abovementioned solvents.

If the medicament is present in multiparticulate form and the active compound is to be released at least partially in delayed form, the release-delaying coating is preferably applied such that the multiparticulate forms comprising the active compound salt are coated after their preparation with the corresponding polymers and, if appropriate, another active compound and/or the same active compound salt and, if appropriate, further physiologically tolerable excipients from aqueous and/or organic media, preferably from aqueous media, with the aid of the fluidized bed process and the coating is preferably simultaneously dried in the fluidized bed at customary temperatures and, if appropriate, annealed if necessary.

Preferably, the drying of the coating is carried out for poly(meth)acrylate coatings at a feed air temperature in the range from 30 to 50 , particularly preferably in the range from 35 to 45 C.

For coatings based on cellulose, such as, for example, ethylcellulose or cellulose acetate, the drying is preferably carried out at a temperature in the range from 50 to 80 C, particularly preferably in the range from 55 to 65 C.

Wax coatings can be applied by melt coating in the fluidized bed and cooled at temperatures below the respective melt range after the coating for complete solidification. The application of wax coatings can also be carried out by spraying on their solutions in organic solvents.
For the modification of the active compound release profile, the medicament according to the invention can contain the pharmaceutical salt whose release is to be delayed also in a release-delaying matrix, preferably uniformly dispersed.

Matrix materials which can be used are physiologically tolerable, hydrophilic materials which are known to the person skilled in the art. Preferably, the hydrophilic matrix materials used are polymers, particularly preferably cellulose ethers, cellulose esters and/or acrylic resins. Very particularly preferably, the matrix materials employed are ethylcellulose, hydroxy-propylmethylcellulose, hydroxypropylcellulose, hydroxy-methylcellulose, poly(meth)acrylic acid and/or their derivatives, such as, for example, their salts, amides or esters.

Likewise preferred are matrix materials made of hydrophobic materials, such as hydrophobic polymers, waxes, fats, long-chain fatty acids, fatty alcohols or appropriate esters or ethers or mixtures of at least two of the abovementioned materials. Particularly preferably, the hydrophobic materials employed are mono- or diglycerides of C12-C30-fatty acids and/or C12-C30-fatty alcohols and/or waxes or mixtures of at least two of the abovementioned materials.

It is also possible to employ mixtures of the above-mentioned hydrophilic and hydrophobic materials as a release-delaying matrix material.

The release-delaying matrix can be prepared by the customary methods known to the person skilled in the art.

A further subject of the invention is also the use of at least one pharmaceutical salt according to the invention and, if appropriate, physiologically tolerable excipients for the production of a medicament. The corresponding medicaments can be used for the treatment of the indications known for the respective active compounds.
Preferred is the use of at least one pharmaceutical salt of a salt-forming opioid, opioid analog, ephedrine, chloroquine, lidocaine, ethaverine, preglumetacin, truflupromazine or a salt-forming compound of the general formula I, II, III or IV
indicated above for the production of a medicament for the control of pain, the salts of these active compounds used preferably being their saccharinates.

Likewise preferred is the use of at least one pharmaceutical salt of a salt-forming compound of the general formula I, II, III or IV indicated above for the production of a medicament for the treatment of urinary incontinence, the salts of these active compounds used preferably being their saccharinates.

The total amount of the respective pharmaceutical salt to be administered to the patient varies, for example, depending on the the weight of the patient, on the indication and the degree of severity of the pain or of the disorder. It is known to the person skilled in the art on account of the properties of the respective active compounds in what doses these are to be administered in order to achieve the desired effect.
The pharmaceutical salts according to the invention of a pharmaceutical active compound and a sugar substitute are distinguished compared with the conventionally used salts of these active compounds customarily by a lower solubility in water. Preferably, these are the saccharinates of the respective active compounds, whose water solubility is usually -< 250 mg/ml and, compared with the water solubility of the conventional salts of the corresponding active compound, is usually lowered by at least 50%.

By this means, the formulation of these pharmaceutical salts to give medicaments, for example the preparation of granules by extrusion, is also simplified. On account of the altered solubility, the pharmaceutical salts according to the invention further enable more effective release-delaying of the active compound using customary delaying processes in comparison to salts customarily used. Delayed-release medicaments which contain these pharmaceutical salts according to the invention can therefore be produced more simply and more inexpensively. This also applies for other modifications of the medicaments according to the invention, such as, for example, with enteric coatings.
From the medicaments according to the invention, which are employed for the administration of the respective pharmaceutical salt via the oral mucosa or the gastric tract, a largely controlled release of the respective active compound without the use of a release-delaying matrix and/or a release-delaying coating, but if appropriate with an enteric coating, is moreover achieved.

The medicaments according to the invention in the form to be administered orally, which release the respective active compound as early as on or immediately after administration, furthermore have the advantage that their strongly bitter or nauseating taste is compensated by the simultaneous release of the sugar substitute. The adherence to the dosage instructions in the patients thereby improves and the medicaments which contain the respective active compound as a salt experience a greater acceptance. The medicaments according to the invention are moreover also suitable for diabetics.
For a large number of the abovementioned active compounds, the water solubility of the conventional active compound salts is known, for example from Pharmazeutische Stoffliste [Pharmaceutical Substance List], 12th edition'ABDATA Pharma-Daten-Service, 65735 Eschborn/Taunus.

If the water solubility of an active compound salt is not known, it can be determined according to the method indicated below, according to which the water solubility of the pharmaceutical salts according to the invention has also been determined:
In a clear colorless vessel made of transparent material, such as, for example, glass or plastic, 1 ml of ion-free water or a fraction (amount A in ml) thereof is introduced at a temperature of 20 C. While stirring with a magnetic stirrer rod, the conventional active compound salt to:be tested or the pharmaceutical salt according to the invention was then added in portions.

If the amount of salt B added (in mg) completely dissolved, further amounts of the respective salt were slowly added. Each further addition was recorded and the solution behavior observed. As soon as the first turbidity due to undissolved salt was found by observation against a suitable background, stirring was continued for a further 10 minutes. If undissolved constituents subsequently remained, the sum C (in mg) of the amount of substance employed was determined. If a clear solution resulted again on stirring, further small amounts of the respective salt were added and the mixture was in each case stirred again for 10 minutes until a first turbidity remained on account of undissolved salts. The excess amount of undissolved substance was then brought into solution with stirring by addition of small amounts of water. After a clear solution had been obtained, the sum D (in ml) of the amount of water employed was determined. The solubility of the respective salt per 1 ml of water was then calculated according to the following formula:

Water solubility of the active compound salt in mg/ml of water = (C/A) + (C/D) If the amount B added (in mg) of the respective salt did not dissolve immediately and a turbidity resulted, after the addition of the salt the mixture was stirred for a further 10 minutes. If undissolved salt still remained then, the undissolved portion was brought into solution by addition of small amounts of water with stirring. After obtainment of a clear solution, the sum E (in ml) of the amounts of water employed was determined. The solubility of the respective salt per 1 ml of water was then calculated according to the following formula:

Water solubility of the active compound salt in mg/ml of water = B
E

The invention is explained below with the aid of examples. These explanations are only by way of example and do not restrict the general inventive concept.
Examples:

Example 1:

The preparation and the subsequent separation of the optically pure compound (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol was carried out according to DE-A-4426245.

For the preparation of (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol saccharinate, 2.58 g (10 mmol) of (+)-(1S,2S)-3-(3-dimethylamino-l-ethyl-2-methylpropyl)phenol hydrochloride and 2.42 g (10 mmol) of saccharin-sodium dihydrate were in each case completely dissolved with warming in an amount of water which was as small as possible. Both solutions were then mixed with one another with stirring and then placed in a cool place overnight. The precipitated (+)-(1S,2S)-3-(3-dimethylamino-l-ethyl-2-methylpropyl)-phenol saccharinate was separated off from the supernatant mother liquor, purified with ethanol and isolated according to conventional methods.
Example 2:

For the preparation of diphenhydramine saccharinate, 5.0 g (17.1 mmol) of diphenhydramine hydrochloride and 4.13 g (17.1 mmol) of saccharin-sodium dihydrate were in each case completely dissolved with warming in an amount of water which was as small as possible. Both solutions were then mixed with one another with stirring and then placed in a cool place overnight. The precipitated diphenhydramine saccharinate was separated off from the supernatant mother liquor, purified with ethanol and isolated according to conventional methods.
Example 3:

For the preparation of verapamil saccharinate, 415 mg (0.845 mmol) of verapamil hydrochloride and 204 mg (0.845 mmol) of saccharin-sodium dihydrate were in each case completely dissolved with warming in an amount of water which was as small as possible. Both solutions were then mixed with one another with stirring and then placed in a cool place overnight. The precipitated verapamil saccharinate was separated off from the supernatant mother liquor, purified with ethanol and isolated according to conventional methods.

Example 4:
For the preparation of morphine saccharinate, 285 mg (0.76 mmol) of morphine hydrochloride trihydrate and 183 mg (0.76 mmol) of saccharin-sodium dihydrate were in each case completely dissolved with warming in an amount of water which was as small as possible. Both solutions were then mixed with one another with stirring and then placed in a cool place overnight. The precipitated morphine saccharinate was separated off from the supernatant mother liquor, purified with ethanol and isolated according to conventional methods.
Example 5:

For the preparation of an oral gel, 0.33 g of methylparaben, 0.05 g of propylparaben and 75.0 g of xylitol were first dissolved in 198.0 g of purified water at a temperature of 80 C and the mixture was then cooled to 40 C. Then, initially 0.94 g of diphenhydramine saccharinate obtained according to example 2 and subsequently 2 g of xanthan gum were added with stirring, stirring was continued for one hour and evaporated water was replaced. After cooling to a temperature of 20 to 25 C, the mixture was flavored with 0.625 g of Tutti-Frutti 9/008897 (Dragoco Gerberding & Co. AG, 37603 Holzminden) while stirring.
Example 6:
5 g of comminuted chewing gum mass (Popeye Amural Confections, Yorkville, Illinois, USA) were warmed to a temperature of 30 to 40 C in a Fanta dish. 187.9 mg of diphenhydramine saccharinate obtained according to example 2 were then incorporated into the viscous chewing gum mass using a pestle. The homogeneous mass was then portioned into teflonized molds to give portions of 1 g each.

The taste test showed that the chewing gums which contained the diphenhydramine saccharinate had an excellent taste at the start and were still enjoyable even after a relatively long chewing time.

Example 7:

For the preparation of a juice on an aqueous basis, 0.33 g of methylparaben, 0.05 g of propylparaben and 75.0 g of xylitol were dissolved in 199.22 g of purified water at a temperature of 80 C. The mixture was cooled to 40 C and 78.5 mg of (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol saccharin-ate obtained according to example 1 were added with stirring. 0.25 g of xanthan gum was then added, stirring was continued for one hour and evaporated water was replaced. After cooling to [lacuna]
temperature of 20 to 25 C, the mixture was flavored while stirring with 0.075 g of orange-mandarin flavor 10888-56 (Givaudan Roure Flavors Ltd. CH 8600 Dtibendorf).

Example 8:
In this example, the water solubility of certain pharmaceutical salts and of conventional salts of the corresponding active compound was determined according to the method indicated above. The solubility values thus obtained are presented in table 1 below:

Table 1:

Comparison of the water solubilities of certain pharmaceutical salts according to the invention and corresponding conventional salts of these active compounds. The conventional salt employed in each case is indicated in brackets.

Active compound Solubility of Solubility of the active the active compound salt compound in mg/ml of saccharinate water in mg/ml of water (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl- 261 31 2-methylpropyl)phenol (hydrochloride) (1RS, 3RS, 6RS) -6-dimethylaminomethyl-1- 500 71 (3-methoxy- (hydrochloride) phenyl) cyclohexane-1,3-diol [sic]
(+)- (1S, 2S) -3- (3-dimethylamino-1-ethyl- 650 55 2-methylpropyl)phenol (hydrochloride) (-) - (1S, 2S) -3- (3-dimethylamino-1-ethyl- 568 130 1-fluoro-2-methyl- (hydrochloride) propyl)phenol (-) - (2S, 3S) -1-dimethylamino-3-(3- 2000 90 methoxyphenyl)- (hydrochloride) Active compound Solubility of Solubility of the active the active compound salt compound in mg/ml of saccharinate water in mg/ml of water 2-methylpentan-3-ol (+)-(1R, 2R, 4S) -2-dimethylaminomethyl-4- 33 10 (4-fluorobenzyl-oxy)- (hydrochloride) 1-(3-methoxy-phenyl)cyclohexanol Morphine 52 25 (hydrochloride trihydrate) Amezinium 25 8 (metilsulfate) Phenylephrine 1250 380 (hydrochloride) Verapamil 200 7 :(hydrochloride) Diphenhydramine 1000 7 (hydrochloride) Benzalkonium 500 < 2 (hydrochloride) Codeine 250 200 (phosphate hemihydrate) Hydromorphone 330 130 (hydrochloride) Buprenorphine 14 2 (hydrochloride) As can be seen from the solubility values according to table 1, the solubility of the respective active compound saccharinates is lowered compared with the corresponding conventional active compound salts.

Claims (34)

1. A pharmaceutical salt of a pharmaceutical active compound and at least one sugar substitute, wherein the salt-forming active compound is a salt-forming 1-phenyl-3-dimethylaminopropane compound of the general formula I

in which X is OH, F, Cl, H or an OCOR6 group, R1 is a C1-4-alkyl group, R2 is H or a C1-4-alkyl group and R3 is H or a straight-chain C1-4-alkyl group or the radicals R2 and R3 together form a C4-7-cycloalkyl radical, and if R5 is H, R4 is meta-O-Z where Z is H, C1-3-alkyl, PO(O-C1-4-alkyl)2, CO(OC1-5-alkyl), CONH-C6H4-(C1-3-alkyl), CO-C6H4-R7, where R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N(R8)2 where R8 is C1-4-alkyl or 4-morpholino, or R4 is meta-S-C1-3-alkyl, meta-Cl, meta-F, meta-CR9R10R11 where R9, R10, R11 are H or F, ortho-OH, ortho-O-C2-3-alkyl, para-F or para-CR9R10R11 where R9, R10, R11 are H or F, or if R5 is para-Cl, -F, -OH or -O-C1-3-alkyl, R4 is meta-Cl, -F, -OH
or -O-C1-3-alkyl, or R4 and R5 together are 3,4-OCH=CH- or 3,4-OCH=CHO-, R6 is C1-3-alkyl, in the form of their possible stereoisomers as racemates or diastereomerically pure enantiomers or in the form of mixtures of enantiomers, in which the respective enantiomers are present in nonequimolar amounts.
2. The pharmaceutical salt as claimed in claim 1, wherein the solubility of the salt in water is <= 250 mg/ml.
3. The pharmaceutical salt as claimed in claim 2, wherein the solubility of the salt in water is selected from <= 200 mg/ml, <= 150 mg/ml, and <= 100 mg/ml.
4. The pharmaceutical salt as claimed in claim 1, 2 or 3, wherein the salt-forming sugar substitute is selected from saccharin, cyclamate and acesulfam.
5. The pharmaceutical salt as claimed in claim 4, where the salt-forming sugar substitute is saccharin.
6. The pharmaceutical salt as claimed in any one of claims 1 to 5, wherein X is OH, F, Cl or H,, R1 is a C1-4-alkyl group, R2 is H or CH3 and R3 is H or CH3 and if R5 is H, R 4 is meta-O-C1-3-alkyl, meta-OH, meta-S-C1-3-alkyl, meta-F, meta-Cl, meta-CH3, meta-CF2H, meta-CF3 or para-CF3 or if R5 is a para-Cl or -F, R4 is meta-Cl or -F, or R4 and R5 together are 3,4-OCH=CH-.
7. The pharmaceutical salt as claimed in any one of claims 1 to 6, wherein the radicals R2 and R3 have different meanings and the compounds of the general formula I as claimed in claim 1 are present in the form of their diastereomers having the configuration Ia
8. The pharmaceutical salt as claimed in any one of claims 1 to 7, wherein the salt-forming 1-phenyl-3-dimethylaminopropane compound is selected from the group consisting of (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-di-methylpropyl)phenol, (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, (2RS,3RS)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol, (-)-(1S,2S)-3-(3-dimethylamino-1-ethyl-1-fluoro-2-methylpropyl)phenol, (+)-(1R,2R)-3-(3-dimethylamino-l-hydroxy-1,2-dimethylpropyl)phenol, (+)-(2R,3R)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and (-)-(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol.
9. The pharmaceutical salt as claimed in claim 8, wherein the salt-forming 1-phenyl-3-dimethylaminopropane compound is (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol.
10. A medicament comprising at least one pharmaceutical salt as claimed in any one of claims 1 to 9 and, optionally, physiologically tolerable excipients.
11. A medicament comprising at least one pharmaceutical salt as claimed in any one of claims 1 to 9 for the control of pain.
12. A medicament comprising at least one pharmaceutical salt as claimed in any one of claims 1 to 9 for the control of urinary incontinence.
13. The medicament as claimed in any one of claims 10 to 12, wherein it is provided in the form of gels, chewing gums, juices, sprays, tablets, chewable tablets, coated tablets, powders, optionally filled into capsules and easily reconstitutable dry preparations.
14. The medicament as claimed in claim 13, wherein said easily reconstitutable dry preparations are selected from gels, aqueous or oily juices, sublingual sprays, tablets and chewable tablets.
15. The medicament as claimed in any one of claims 10 to 12, formulated in multiparticulate form.
16. The medicament of claim 15, wherein said multiparticulate form is selected from the group consisting of microtablets, microcapsules, granules, active compound crystals and pellets.
17. The medicament of claim 16, wherein said microtablets, granules or pellets are filled into capsules or compressed to give tablets.
18. The medicament of claim 15, wherein said multiparticulate form is a microtablet, granulate or pellet.
19. The medicament of claim 18, wherein said microtablet, granule or pellet is compressed to form a tablet.
20. The medicament as claimed in any one of claims 10 to 19, wherein the salt is present at least partially in delayed-release form.
21. The medicament as claimed in claim 20, wherein said delayed-release form is provided by one or more of a release-delaying coating, embedding in a release-delaying matrix and binding to an ion-exchange resin.
22. The medicament as claimed in claim 21, wherein the release-delaying coating is based on one or more of a water-insoluble, optionally modified natural or synthetic polymer, or on a natural, semisynthetic or synthetic wax or fat or fatty alcohol.
23. The medicament as claimed in claim 22, wherein said polymer is further provided in combination with a customary plasticizer.
24. The medicament as claimed in claim 21, wherein said matrix is based on a hydrophilic matrix material.
25. The medicament of claim 24, wherein said hydrophilic matrix material is a hydrophilic polymer.
26. The medicament of claim 25, wherein said hydrophilic polymer is selected from one or more of cellulose ethers, cellulose esters and acrylic resins.
27. The medicament of claim 26, wherein said cellulose ethers, cellulose esters and acrylic resin are selected from one or more of ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, poly(meth)acrylic acid and/or their their salts, amides and esters.
28. The medicament as claimed in claim 21, wherein the matrix is a hydrophobic matrix material.
29. The medicament of claim 28, wherein said hydrophobic matrix material is a hydrophobic polymer, wax, fat, long-chain fatty acid, fatty alcohols or esters or ethers or their mixtures.
30. The medicament of claim 29, wherein said hydrophobic matrix materials is a mono- or diglyceride of C12-C30 fatty acids and/or C12-C30-fatty alcohols and/or waxes or their mixtures.
31. The medicament as claimed in any one of claims 10 to 28, wherein said medicament has a protective coating.
32. The medicament as claimed in claim 31, wherein said protective coating is an enteric protective coating.
33. Use of at least one pharmaceutical salt as claimed in any one of claims 1 to 8 for the control of pain.
34. Use of at least one pharmaceutical salt as claimed in any one of claims 1 to 8 for the control of urinary incontinence.
CA2439269A 2001-02-28 2002-02-28 Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds Expired - Lifetime CA2439269C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2725635A CA2725635A1 (en) 2001-02-28 2002-02-28 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10109763A DE10109763A1 (en) 2001-02-28 2001-02-28 Pharmaceutical salts
DE10109763.8 2001-02-28
PCT/EP2002/002169 WO2002067916A2 (en) 2001-02-28 2002-02-28 Pharmaceutical salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2725635A Division CA2725635A1 (en) 2001-02-28 2002-02-28 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds

Publications (2)

Publication Number Publication Date
CA2439269A1 CA2439269A1 (en) 2002-09-06
CA2439269C true CA2439269C (en) 2011-11-01

Family

ID=7675871

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2725635A Abandoned CA2725635A1 (en) 2001-02-28 2002-02-28 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds
CA2439269A Expired - Lifetime CA2439269C (en) 2001-02-28 2002-02-28 Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2725635A Abandoned CA2725635A1 (en) 2001-02-28 2002-02-28 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds

Country Status (25)

Country Link
EP (1) EP1390023B1 (en)
JP (2) JP4737583B2 (en)
KR (1) KR20030078943A (en)
CN (2) CN100352431C (en)
AR (1) AR033423A1 (en)
AT (1) ATE395053T1 (en)
BR (1) BR0207726A (en)
CA (2) CA2725635A1 (en)
CZ (1) CZ306998B6 (en)
DE (2) DE10109763A1 (en)
ES (1) ES2307739T3 (en)
HK (1) HK1064035A1 (en)
HU (1) HU229048B1 (en)
IL (2) IL157477A0 (en)
MX (1) MXPA03007712A (en)
NO (1) NO333986B1 (en)
NZ (2) NZ551440A (en)
PE (1) PE20020973A1 (en)
PL (1) PL218187B1 (en)
PT (1) PT1390023E (en)
RU (1) RU2309942C2 (en)
SI (1) SI1390023T1 (en)
SK (1) SK287574B6 (en)
WO (2) WO2002067651A2 (en)
ZA (2) ZA200410015B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133142B2 (en) 2010-07-23 2015-09-15 Gruenenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030527A1 (en) 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
CN1298317C (en) * 2001-11-07 2007-02-07 斯索恩有限公司 Tamsulosin tablets
DE10163421A1 (en) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Use of (+) - (1S, 2S) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol as an anti-emetic
DE10224556A1 (en) * 2002-05-31 2004-01-08 Grünenthal GmbH Medicament containing 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol in various formulations
DE10225315A1 (en) * 2002-06-06 2003-12-24 Gruenenthal Gmbh Active substance salts and esters of 1-dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl) - phenol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004028512A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage form with two cores
DE50309605D1 (en) 2002-11-22 2008-05-21 Gruenenthal Gmbh Use of (1RS, 3RS, 6RS) -6-dimethylaminomethyl-1- (3-methoxyphenyl) -cyclohexane-1,3-diol for the treatment of inflammatory pain
DE10305984A1 (en) * 2003-02-13 2004-09-02 Helm Ag Salts of organic acids with clopidogrel and their use in the manufacture of pharmaceutical formulations
DE10329386A1 (en) * 2003-06-30 2005-01-20 Novartis Ag Aqueous solution containing opipramol salt, useful for treating depression, also includes a sugar alcohol or synthetic sweetener to improve taste and chemical stability, particularly color
DE10333835A1 (en) * 2003-07-24 2005-03-10 Gruenenthal Gmbh Sustained-release drug containing 6-dimethylaminomethyl-1- (3-methoxy-phenyl) -cyclohexane-1,3-diol
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10356362A1 (en) * 2003-11-28 2005-06-23 Grünenthal GmbH Use of 1-phenyl-3-dimethylamino-propane compounds for the treatment of anxiety disorders
FR2865648B1 (en) * 2004-02-03 2006-06-30 Philippe Perovitch METHOD FOR DIFFUSION OF INSOLUBLE MOLECULES IN AQUEOUS MEDIUM AND COMPOSITION IMPLEMENTING SAID METHOD
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
WO2006046560A1 (en) * 2004-10-29 2006-05-04 Taiho Pharmaceutical Co., Ltd. Propiverine-containing oral particulate preparation and process for producing the same
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
BRPI0502736A (en) * 2005-07-05 2007-02-27 Biolab Sanus Farmaceutica Ltda oral formulations of masked residual flavor ondansetron
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) * 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
ATE502629T1 (en) * 2006-04-28 2011-04-15 Gruenenthal Gmbh PHARMACEUTICAL COMBINATION WITH 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL AND AN NSAID
DE102007022790A1 (en) 2007-05-11 2008-11-20 Grünenthal GmbH Axomadol for the treatment of pain in osteoarthritis
JP2009007311A (en) * 2007-06-29 2009-01-15 Lintec Corp Diphenhydramine-acesulfame adduct, method for producing the same and oral preparation containing the adduct
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
JP5755224B2 (en) * 2009-06-08 2015-07-29 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ Extruded particles
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533586A (en) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Oxidation-stabilized tamper-resistant dosage form
PL2611426T3 (en) 2010-09-02 2014-09-30 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
AU2012224953C1 (en) * 2011-03-04 2017-07-13 Grünenthal GmbH Parenteral administration of tapentadol
CA2839126A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
LT2736495T (en) 2011-07-29 2017-11-10 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (en) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (en) 2013-05-29 2015-12-30 Gruenenthal Gmbh DOSAGE FORM RESISTANT TO INDEBITED USE WITH BIMODAL RELEASE PROFILE, PROCESS
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105934241B (en) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 Preparation of powdered pharmaceutical composition by cryogenic grinding
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
CA2949422A1 (en) 2014-05-26 2015-12-03 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
RU2588840C1 (en) * 2015-03-26 2016-07-10 Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" Tablet quetiapine with prolonged release and synthesis method thereof
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
US9833408B1 (en) * 2016-07-28 2017-12-05 Allen Greenspoon Orally administrable formulation
KR20190057349A (en) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
DE202020104285U1 (en) 2020-07-24 2020-12-18 Grünenthal GmbH Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362730A (en) * 1980-08-25 1982-12-07 Heinrich Mack Nachf. Chem-Pharm. Fabrik Vincamine saccharinate and a pharmaceutical composition containing it dissolved therein
DE3113132A1 (en) * 1981-04-01 1982-10-21 Heinrich Mack Nachf., 7918 Illertissen VINCAMINE CYCLAMATE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THIS
DE3639902A1 (en) * 1986-11-22 1988-06-01 Bayer Ag SACCHARINE SALTS FROM SUBSTITUTED HYDROXYPROPYLAMINES
DE3639901A1 (en) * 1986-11-22 1988-06-01 Bayer Ag SACCHARINE SALTS FROM SUBSTITUTED AMINES
DE3639903A1 (en) * 1986-11-22 1988-06-01 Bayer Ag SACCHARINE SALTS OF AMINOMETHYLHETEROCYCLEN
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
DE4426245A1 (en) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
DE19525137C2 (en) * 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as intermediates for the preparation of pharmaceutical agents
DE19601744C2 (en) * 1996-01-19 1998-04-16 Gruenenthal Gmbh Process for the preparation of the enantiomers of O-demethyltramadol
EP1136498A1 (en) * 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
JP2003525855A (en) * 1998-08-27 2003-09-02 ブリストル−マイヤーズ スクイブ カンパニー New drug salt form
IL148411A0 (en) * 1999-08-31 2002-09-12 Gruenenthal Chemie Delayed-action form of administration containing tramadol saccharinate
DE19947747A1 (en) * 1999-10-05 2001-04-12 Gruenenthal Gmbh Treatment of urinary incontinence using (+)-tramadol, O-demethyl-tramadol or O-demethyl-N-mono-desmethyl-tramadol, having strong effect on bladder function without side-effects or analgesic action
DE10013259A1 (en) * 2000-03-17 2001-09-20 Nutrinova Gmbh New stable complexes of acesulfame with trace elements e.g. zinc or copper, useful as taste-masked form of trace elements for use in foods, feedstuffs, pharmaceuticals or cosmetics
DE10013712A1 (en) * 2000-03-20 2001-09-27 Nutrinova Gmbh Nicotine salts with improved taste, process for their preparation and their use
DE10059412A1 (en) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Use of 1-phenyl-3-dimethylamino-propane compounds for the treatment of urinary incontinence
DE10130298A1 (en) * 2001-06-22 2003-01-23 Nutrinova Gmbh Antimicrobial acesulfame complexes, process for their preparation and their use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133142B2 (en) 2010-07-23 2015-09-15 Gruenenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US9446008B2 (en) 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
US11547678B2 (en) 2011-03-04 2023-01-10 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
US11013701B2 (en) 2015-03-27 2021-05-25 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol

Also Published As

Publication number Publication date
JP2011079843A (en) 2011-04-21
AR033423A1 (en) 2003-12-17
ATE395053T1 (en) 2008-05-15
IL157477A0 (en) 2004-03-28
DE50212273D1 (en) 2008-06-26
HUP0303325A2 (en) 2004-01-28
WO2002067651A2 (en) 2002-09-06
RU2003127396A (en) 2005-03-20
CA2439269A1 (en) 2002-09-06
RU2309942C2 (en) 2007-11-10
PT1390023E (en) 2008-07-30
NZ551440A (en) 2007-08-31
ZA200306529B (en) 2005-03-30
HUP0303325A3 (en) 2008-03-28
BR0207726A (en) 2004-07-27
SK287574B6 (en) 2011-03-04
EP1390023A2 (en) 2004-02-25
KR20030078943A (en) 2003-10-08
WO2002067916A2 (en) 2002-09-06
WO2002067916A3 (en) 2003-12-18
SK10612003A3 (en) 2004-01-08
NZ528302A (en) 2007-02-23
HK1064035A1 (en) 2005-01-21
JP2004527491A (en) 2004-09-09
MXPA03007712A (en) 2004-03-16
HU229048B1 (en) 2013-07-29
CN100352431C (en) 2007-12-05
SI1390023T1 (en) 2008-10-31
ES2307739T3 (en) 2008-12-01
IL157477A (en) 2009-12-24
CA2725635A1 (en) 2002-09-06
JP4737583B2 (en) 2011-08-03
ZA200410015B (en) 2005-09-28
PE20020973A1 (en) 2002-10-26
DE10109763A1 (en) 2002-09-05
CZ20032315A3 (en) 2003-11-12
NO333986B1 (en) 2013-11-04
NO20033815L (en) 2003-09-09
PL218187B1 (en) 2014-10-31
PL364223A1 (en) 2004-12-13
NO20033815D0 (en) 2003-08-27
CN1561203A (en) 2005-01-05
CN101125137A (en) 2008-02-20
EP1390023B1 (en) 2008-05-14
CZ306998B6 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
CA2439269C (en) Pharmaceutical salts of 1-phenyl-3-dimethylaminopropane compounds
US10160719B2 (en) Pharmaceutical salts
US9072700B2 (en) Methods of using derivatives of (−)-venlafaxine
US6197828B1 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
EP1466889B1 (en) O-Desmethylvenlafaxine succinate
CZ2002674A3 (en) Tramadol pharmaceutical salts, medicaments containing those compounds and their use
RU2305562C2 (en) Combination of specific opioids with muscarine antagonists for incontinence therapy
AU2002353206B2 (en) Treatment of faecal incontinence and other conditions with 1R, 2S-Methoxamine
US7687520B2 (en) Serotonin and norepinephrine reuptake inhibitors and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220228